Dual-energy computed tomography for the assessment of early treatment effects of regorafenib in a preclinical tumor model: comparison with dynamic contrast-enhanced CT and conventional contrast-enhanced single-energy CT

Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247

Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124

Benjamin RS, Choi H, Macapinlac HA et al (2007) We should desist using RECIST, at least in GIST. J Clin Oncol : Off J Am Soc Clin Oncol 25(13):1760–1764

Choi H, Charnsangavej C, Faria SC et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol : Off J Am Soc Clin Oncol 25(13):1753–1759

Ratain MJ, Eisen T, Stadler WM et al (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol 24(16):2505–2512

Faivre S, Delbaldo C, Vera K et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol Off J Am Soc Clin Oncol 24(1):25–35

Choi H (2005) Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model. Curr Oncol Rep 7(4):307–311

Goh V, Halligan S, Daley F, Wellsted DM, Guenther T, Bartram CI (2008) Colorectal tumor vascularity: quantitative assessment with multidetector CT–do tumor perfusion measurements reflect angiogenesis? Radiology 249(2):510–517

d’Assignies G, Couvelard A, Bahrami S et al (2009) Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors. Radiology 250(2):407–416

Kan ZX, Phongkitkarun S, Kobayashi S et al (2005) Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model. Radiology 237(1):151–158

Lee TY, Purdie TG, Stewart E (2003) CT imaging of angiogenesis. Q J Nucl Med 47(3):171–187

Lind JS, Meijerink MR, Dingemans AM et al (2010) Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment? Eur Radiol 20(12):2890–2898

Cyran CC, Kazmierczak PM, Hirner H et al (2013) Regorafenib effects on human colon carcinoma xenografts monitored by dynamic contrast-enhanced computed tomography with immunohistochemical validation. PLoS ONE 8(9):e76009

Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK (1996) Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 93(25):14765–14770

Winklehner A, Goetti R, Baumueller S et al (2011) Automated attenuation-based tube potential selection for thoracoabdominal computed tomography angiography: improved dose effectiveness. Invest Radiol 46(12):767–773

Pontana F, Duhamel A, Pagniez J et al (2011) Chest computed tomography using iterative reconstruction vs filtered back projection (Part 2): image quality of low-dose CT examinations in 80 patients. Eur Radiol 21(3):636–643

Brix G, Griebel J, Kiessling F, Wenz F (2010) Tracer kinetic modelling of tumour angiogenesis based on dynamic contrast-enhanced CT and MRI measurements. Eur J Nucl Med Mol Imaging 37(Suppl 1):S30–S51

Johnson TRC, Krauss B, Sedlmair M et al (2007) Material differentiation by dual energy CT: initial experience. Eur Radiol 17(6):1510–1517

Henzler T, Fink C, Schoenberg SO, Schoepf UJ (2012) Dual-Energy CT: Radiation Dose Aspects. Am J Roentgenol 199(5):S16–S25

Schenzle JC, Sommer WH, Neumaier K et al (2010) Dual Energy CT of the Chest: How About the Dose? Invest Radiol 45(6):347–353

Kerl JM, Bauer R, Maurer T et al (2011) Dose levels at coronary CT angiography—a comparison of dual energy-, dual source- and 16-slice CT. Eur Radiol 21(3):530–537

Zordo T, Lutterotti K, Dejaco C et al (2012) Comparison of image quality and radiation dose of different pulmonary CTA protocols on a 128-slice CT: high-pitch dual source CT, dual energy CT and conventional spiral CT. Eur Radiol 22(2):279–286

Simons D, Kachelriess M, Schlemmer HP (2014) Recent developments of dual-energy CT in oncology. Eur Radiol 24(4):930–939

Eisen T, Joensuu H, Nathan PD et al (2012) Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol 13(10):1055–1062

Wilhelm SM, Dumas J, Adnane L et al (2011) Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129(1):245–255

Mahnken AH, Klotz E, Pietsch H et al (2010) Quantitative whole heart stress perfusion CT imaging as noninvasive assessment of hemodynamics in coronary artery stenosis: preliminary animal experience. Invest Radiol 45(6):298–305

Jost G, Pietsch H, Grenacher L (2013) Dynamic contrast-enhanced computed tomography to assess antitumor treatment effects: comparison of two contrast agents with different pharmacokinetics. Invest Radiol 48(10):715–721

Apfaltrer P, Meyer M, Meier C et al (2012) Contrast-enhanced dual-energy CT of gastrointestinal stromal tumors: is iodine-related attenuation a potential indicator of tumor response? Invest Radiol 47(1):65–70

Dai X, Schlemmer HP, Schmidt B et al (2013) Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib. Eur J Radiol 82(2):327–334